EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Development of the retinoic acid receptor alpha-specific antagonist YCT-529 for male contraception: A brief review

Rui Shi, Debra J Wolgemuth, Gunda I Georg

Contraception · 2025-05 · 145 · 110809

DOI: 10.1016/j.contraception.2024.110809 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Contraception, 2025-05. Verfasst von Rui Shi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, College of Pharmacy, University of Minnesota, Minneapolis…. Hauptthemen laut MEDLINE: Retinoic Acid Receptor alpha, Contraceptive Agents, Male, Indazoles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NICHD NIH HHS, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute of Child Health and Human Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Retinoic Acid Receptor alphaContraceptive Agents, MaleIndazolesMaleAnimalsHumansMiceSpermatogenesisContraception

Stichwörter der Autor:innen

AntagonistMale contraceptionReversibilitySpermatogenesis inhibitionVitamin A

Substanzen

Retinoic Acid Receptor alphaContraceptive Agents, MaleIndazoles

Autor:innen und Institutionen

  • Department of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, College of Pharmacy, University of Minnesota, Minneapolis, MN, United States.
  • Department of Genetics and Development, Columbia University Medical Center, New York, NY, United States; Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, NY, United States; T…
  • Department of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, College of Pharmacy, University of Minnesota, Minneapolis, MN, United States. Electronic address: georg@umn.edu.

Förderung

  • NICHD NIH HHS
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • National Institute of Child Health and Human Development

Zitieren

APA

Shi, R., Wolgemuth, D. J., & Georg, G. I. (2025). Development of the retinoic acid receptor alpha-specific antagonist YCT-529 for male contraception: A brief review. Contraception, 145, 110809. https://doi.org/10.1016/j.contraception.2024.110809

Vancouver

Shi R, Wolgemuth DJ, Georg GI. Development of the retinoic acid receptor alpha-specific antagonist YCT-529 for male contraception: A brief review. Contraception. 2025;145:110809. doi:10.1016/j.contraception.2024.110809

BibTeX
@article{Shi2025,
  author = {Shi, Rui and Wolgemuth, Debra J and Georg, Gunda I},
  title = {Development of the retinoic acid receptor alpha-specific antagonist YCT-529 for male contraception: A brief review},
  journal = {Contraception},
  year = {2025},
  volume = {145},
  pages = {110809},
  doi = {10.1016/j.contraception.2024.110809}
}
Kostenlos starten →